Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes.

Nutsiwat DidasWitsawat ThitisopeeSureerut PorntadavityNutjaree Jeenduang

Published in: International urology and nephrology (2020)

Reduced AREase activity can increase the risk for CKD in T2DM patients. AREase activity, but not PONase activity and PCSK9 levels, may be used as the biomarker for predicting the progression of CKD in T2DM.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
cardiovascular disease
newly diagnosed
insulin resistance
metabolic syndrome
low density lipoprotein